Saracatinib trial TO Prevent FOP

STOPFOP

Information

The aim of this study is to investigate the efficacy and safety of the new drug AZD0530 (saracatinib) for treating patients with Fibrodysplasia Ossificans Progressiva (FOP). You can read more about FOP here. Beneath, you can find additional information about the study. If you have any additional questions after reading this information, please feel free to contact the researchers. 

What participating means for you

Before you decide to participate or not, the research physisican will inform you extensively about what participating in the study means for you. 

If you decide to participate, the study will last about one and a half years for you. During this period you will have to visit the hospital 10 times. During these visits several tests will be performed, these include blood draws and PET-CT scans.

If you are interested of have any questions, please feel free to contact the researchers. 

Tip: Also watch the video with explanation below!

 

Who can apply?

This study is performed in men and women with FOP between 18 and 65 years of age. A research physician will first determine if someone is eligible for the study. The research physician will perform several tests, ask about medical history and look at drug use. 

 
News
Press releases

The Saracatinib trial to prevent Fibrodysplasia Ossificans Progressiva (STOPFOP) will begin... read more 

The STOPFOP team recently announced that enrollment for our clinical trial had started. Unfortunately... read more 

Videos
 
Consortium Partners
Amsterdam_UMC_Logo.jpg
BWH_logo_rgb_pos.jpg
download (1).png
6D9A-C606-42CA-82EA-0CA2.png
65f07ff4a9103b098fd9e942c558a29d3eb3861e

We collaborate with members of patient organisations through our Stakeholders Board with members of: IFOPA and national FOP patient organisations from: The Netherlands, United Kingdom, Germany, France, Italy and Sweden.

 

Contact

 
image-7.png
flag_yellow_high.jpg
logo-efpia.jpg

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 821600. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.